You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 11, November 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, LONDON, APRIL 27 TO APRIL 30, 1987-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Hyperthermic Pelvic Isolation-Perfusion in the Treatment of Refractory Pelvic Cancer

Alan Wile, MD; Michael Smolin, MD

Arch Surg. 1987;122(11):1321-1325.


Abstract

• Hyperthermic isolation-perfusion (I-P) was used to treat 27 patients with refractory pelvic cancer. All patients except one achieved pelvic isolation as manifested by selective pelvic heating and by pharmacologic monitoring. Patient response was good, with rapid pain relief in 75% and tumor control as detected by physical examination, computed tomographic scan, and decline in carcinoembryonic antigen levels. Pelvic drug exposure averaged 7.8 times that of systemic drug exposure. Of the 20 patients with recurrent rectal adenocarcinoma, one complete response (duration, eight months), seven partial responses (average duration, ≥10 months), four patients with stable disease (average duration, ≥12 months), and five with disease progression were observed. Three patients could not be evaluated due to late deaths as a consequence of their disease. There were two postoperative deaths in the remaining seven patients, one due to drug toxicity and one due to probable cardiac arrhythmia. Pelvic I-P has evolved with the avoidance of laparotomy and increased drug dose. We conclude that hyperthermic I-P for pelvic cancer is a safe, effective procedure and an excellent therapeutic option for patients with persistent pelvic cancer.

(Arch Surg 1987; 122:1321-1325)



Author Affiliations

From the Departments of Surgery (Dr Wile) and Radiology (Dr Smolin), University of California Irvine Medical Center, Orange.


Footnotes

Accepted for publication Aug 4, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 29, 1987.

Reprint requests to Division of Surgical Oncology, Department of Surgery, University of California Irvine Medical Center, 101 City Dr South, Orange, CA 92668 (Dr Wile).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypoxic Pelvic Perfusion With Mitomycin C Using a Simplified Balloon-Occlusion Technique in the Treatment of Patients With Unresectable Locally Recurrent Rectal Cancer
Guadagni et al.
Arch Surg 2001;136:105-112.
ABSTRACT | FULL TEXT  

Isolated Pelvic Perfusion for Unresectable Cancer Using a Balloon Occlusion Technique
Turk et al.
Arch Surg 1993;128:533-539.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.